RxDoctor Payments Data

Ali Ahmad, MD

Cardiovascular Disease · Tiffin, OHNPI 1780980987

Payments from drug & device makers

$812in general payments, 2019–2025

Across 50 payments — averaging $16.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bardy Diagnostics, Inc.$402
  • Johnson & Johnson$69
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$45
  • Boston Scientific$44
  • Vital Connect, Inc$43
  • E.r. Squibb & Sons, L.L.C.$41
  • plus $168 from 7 others

What the payments were for

  • Food & beverage$79898%
  • Education$142%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$812 in reported general payments places this provider in the 35th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$220,683
Medicare patients
1,676
Services billed
4,992

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban210$231,572
XareltoRivaroxaban53$54,862
BrilintaTicagrelor53$47,304
EntrestoSacubitril/Valsartan31$40,980
FarxigaDapagliflozin Propanediol31$26,278
MultaqDronedarone Hcl12$20,133
JardianceEmpagliflozin14$19,450
Metoprolol Succinate543$7,127
Dofetilide19$6,412
Midodrine Hcl46$4,654
Ezetimibe146$3,561
Ranolazine ErRanolazine24$2,891
Atorvastatin Calcium299$2,707
Losartan Potassium188$2,009
Prasugrel Hcl18$1,920

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$29$231,572210 claims
AstraZenecaBrilinta, Farxiga$11$73,58384 claims
Johnson & JohnsonXarelto$69$54,86253 claims
NovartisEntresto$31$40,98031 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Tiffin

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →